Revolutionary Advances in Women's Health: The DARE to PLAY™ Webinar
Introducing a groundbreaking solution tailored for women’s sexual arousal - incorporating the same active ingredient found in Viagra but in a unique topical formula that addresses women's specific needs.
Set to be available through prescription by the end of 2025.
SAN DIEGO — Daré Bioscience, Inc. (NASDAQ: DARE) continuously innovates in the biopharmaceutical space, focusing exclusively on women's health. Today, the company announced an engaging live webinar on a pioneering solution for female sexual arousal, highlighting the unique DARE to PLAY™ cream, the first evidence-supported sildenafil formulation specifically designed for women.
This insightful event, titled The DARE to PLAY™ Difference: The Sildenafil Cream That Raises the Bar, will take place in collaboration with The National Association of Nurse Practitioners in Women’s Health (NPWH). The webinar centers on a revolutionary topical sildenafil preparation, clinically shown to enhance genital blood flow and sexual response in women. Unlike other unverified products, DARE to PLAY™ is rooted in scientific research and is precisely formulated to deliver sildenafil where it can be most effective, bridging a significant gap in women’s health solutions.
Leading sexual health professionals will participate in the webinar, featuring three notable experts, including Dr. Irwin Goldstein, a renowned clinician who has extensively researched sildenafil for over twenty years. These experts will discuss how DARE to PLAY™ is transforming perceptions surrounding female sexual arousal, offering women a trustworthy, validated option.
Key Highlights of the Webinar
The webinar promises several engaging topics, such as:
- Understanding the critical role of genital blood flow in women’s arousal and how DARE to PLAY™ effectively facilitates this.
- Review of clinical studies demonstrating enhancements in arousal, orgasm, and overall desire in women using DARE to PLAY™.
- The unique formulation of DARE to PLAY™ and its significance to the product’s success.
- How Daré’s expertise in formulation and clinical development is addressing pressing needs in women’s health.
Participants in the webinar will also gain access to a product alert list, ensuring they are promptly informed when DARE to PLAY™ becomes available by prescription in late 2025.
This event is designed for a diverse audience, including healthcare professionals, investors, and women interested in scientifically grounded approaches to enhance their sexual health.
Webinar Details
Title: The DARE to PLAY™ Difference: The Sildenafil Cream That Raises the Bar
Speakers:
- Rose Hartzell-Cushanick, AASECT Certified Sex Therapist
- Sue Goldstein, CCRC, CSE, an influential figure in women’s sexual health
- Irwin Goldstein, MD, Founding Editor of The Journal of Sexual Medicine
Date: Wednesday, August 6, 2025
Time: 12:00 PM ET
About Daré Bioscience
Daré Bioscience is dedicated to making a significant impact in women’s health. The company is committed to advancing evidence-based solutions to resolve historical unmet needs in areas such as contraception, sexual health, and menopause. Daré’s innovative approach taps into existing clinical evidence and safety data, optimizing pathways to market that prioritize women’s access to these solutions.
Among its innovative products, Daré has launched XACIATO™ (clindamycin phosphate) vaginal gel 2%, specifically for bacterial vaginosis treatment, under a global licensing agreement. Other groundbreaking candidates include Ovaprene®, a hormone-free contraceptive, and the DARE-HRT1 hormone therapy solution. For further information, please visit the official Daré Bioscience website.
Daré Bioscience has either established or is progressing novel products aimed at filling critical gaps in women's health. The leadership team has been recognized for its contributions to women’s health innovations and advocacy, further solidifying the company’s role in the industry.
Frequently Asked Questions
What is the main focus of Daré Bioscience?
Daré Bioscience focuses on advancing women's health through innovative and evidence-based solutions that address unmet medical needs.
What is the DARE to PLAY™ cream?
DARE to PLAY™ is a topical sildenafil cream designed specifically for women to enhance sexual arousal and response.
When will the DARE to PLAY™ cream be available?
The DARE to PLAY™ cream is expected to be available by prescription in the fourth quarter of 2025.
Who will be speaking at the webinar?
The webinar will feature leading sexual health professionals, including Rose Hartzell-Cushanick, Sue Goldstein, and Dr. Irwin Goldstein.
Why is there a need for products like DARE to PLAY™?
There is a long-standing gap in effective sexual health treatments for women, and products like DARE to PLAY™ aim to provide clinically validated solutions.
